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dynamics such as encountered in young patients after
AVR with homografts or autografts.2,3
Mechanical valves and, to a greater degree, stent-
mounted biologic valves expose patients to a higher risk
of residual gradients, especially patients with a small
aortic root and a body surface area (BSA) exceeding
1.70 m2, or when expected orifice area index is below
0.80 cm2/m2. This quantitative frame allows us to define
replacement device mismatch,4 although its anticipated
significance may vary with age groups and be of greater
significance in young and active patients.
Compared with stent mounted valves, stentless bio-
logic valves offer superior hemodynamic profiles.5-9
The improved effective orifice areas and lower residual
gradients were expected to reduce incidence, if not
completely rule out mismatch. This multicenter study
evaluated the aptitude of the CryoLife-O’Brien
(CryoLife International, Marietta, Ga) stentless porcine
valve to achieve optimum hemodynamics in elderly
patients who have a small aortic root with a measured
aortic anulus of 19 or 21 mm. Differences in valve cal-
ibration by 3 manufacturers and oversizing the selected
device by the surgeon are the reasons we preferred to
O btaining optimal hemodynamics after aortic valvereplacement (AVR) may be a more pertinent goal
than previously considered. It is possible that low gra-
dients, correlating with completeness of regression of
left ventricular (LV) hypertrophy and better recovery of
LV function, could enhance event-free patient out-
come.1 Although no data yet establish firmly that mis-
match reduces long-term survival, such intuitive
expectancy is leading surgeons to be concerned that an
adequate-sized replacement device be used and that
even elderly patients should benefit from optimal hemo-
Objective: A clinical study was conducted to evaluate the results of stent-
less porcine valves in patients with a small aortic root (19- and 21-mm
aortic anulus). Methods: Of 567 patients, from 4 surgical institutions, 171
patients (30.1%) had a small aortic root, comprising 163 cases with cal-
cified aortic stenosis and 8 cases with predominant valvular insufficien-
cy. Sixty patients had associated mitral or coronary lesions. Mean age
was 72 ± 4.2 years. Forty-seven patients with a small aortic root had a
19-mm anulus, and 124 patients had a 21-mm anulus. The body surface
area was, respectively, 1.55 ± 0.2 m2 and 1.78 ± 0.45 m2. Hemodynamic
evaluation of the stentless valve comprised serial measures of mean gra-
dients, effective orifice area, and left ventricular mass reduction.
Complication rates for secondary events were evaluated over a 6-year
period. Results: The hospital mortality rate was 3.5%. The mean gradi-
ents after the first year were 9 ± 2 mm Hg and 6 ± 1.7 mm Hg in patients
with a 19-mm and a 21-mm anulus, respectively. Effective orifice area
was 1.45 ± 0.3 cm2 and 1.72 ± 0.4 cm2. Gradients and surfaces remained
stable throughout the study period. Aortic regurgitation was zero to
trace. Left ventricular mass at discharge and at 1 year were, respective-
ly, 296 ± 127 g and 215 ± 102 g for patients with a 19-mm anulus and 281
± 75 g and 236 ± 15 g for patients with a 21-mm anulus. Conclusions:
Stentless valves are a suitable device for elderly patients with small aor-
tic roots, which leave only mild residual obstruction. (J Thorac
Cardiovasc Surg 1999;117:267-72)
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MULTICENTER STUDY OF STENTLESS VALVE REPLACEMENT IN THE SMALL AORTIC ROOT
define the small aortic root by the intraoperative mea-
sured size of the aortic anulus and not according to the
size of the device inserted.
Patients and methods
Patient population. Between September 1991 and
September 1997, 567 patients received a CryoLife-O’Brien
stentless porcine aortic valve in one of the four referral hos-
pitals. Of this group, 171 patients (30.1%) had a small aortic
root. These patients had an aortic anulus, measured in the
operating room by means of a Hegar dilator, with a diameter
of 19 or 21 mm. Patient characteristics are shown in Table I.
As with all series dealing with calcified aortic stenosis in
elderly patients, most are women who are symptomatic and in
sinus rhythm. In the group, 93.6% of patients (44 of 47
patients) were women with a 19-mm aortic anulus, and
64.5% of patients (80 of 124 patients) had a 21-mm anulus.
The prevalence of patients with a 19- or 21-mm aortic anulus
was 8.2% (47 of 567 patients) and 21.8% (124 of 567
patients), respectively.
The study valve. The CryoLife-O’Brien stentless porcine
aortic prosthesis (Fig 1) is a composite design, constructed
with noncoronary leaflets obtained from 3 porcine valves.
Leaflets are carefully excised from valves already fixed in
glutaraldehyde under low or near zero pressure. Individual
noncoronary leaflets are matched for size and symmetry to
assure synchronous opening and to promote maximum leaflet
coaptation. The matched set of leaflets is sutured together
along the free edges of the porcine aortic wall at the leaflet
commissures. The base of the valve is finished with a blanket
stitch to assure its integrity. No Dacron reinforcement is nec-
essary, which is a significant difference when compared with
other stentless valves.
Surgical technique
Valve size selection. After removing the native valve, we
feel that it is important to debride all the calcium on the anu-
lus and, at times, necessary to peel off calcifications from the
Valsalva sinus and the sinotubular junction, which results in a
much more flexible aortic root. The aortic anulus is measured
with a Hegar dilator. Being seated above the anulus, the
selected valve must offer the same internal diameter as the
measured transannular diameter. For instance, a 21-mm
xenograft with an internal diameter of 19 mm will match a
measured transannular diameter of 19 mm, and a patient with
a 21-mm aortic anulus will receive a 23-mm graft. This does
not correspond to oversizing, and the scalloped CryoLife-
O’Brien valve will sit in a natural position within the Valsalva
sinus. Keeping to these selection rules, the surgeon can be
confident that the valve will be seated correctly in the
Valsalva sinus above the anulus and that the xenograft will
offer the maximum effective orifice area (EOA). The implan-
tation technique is simple and needs only one running suture
line as previously reported.6,7 None of the patients underwent
a procedure of annular enlargement.
Echocardiography. All patients underwent preoperative
transthoracic echocardiography. The referring cardiologist, to
assess valve function, monitored all survivors with serial
transthoracic echocardiograms, the first before discharge, at 6
months, and then at least annually. Transvalvular gradients
and LV mass were available for all patients except for those
who had not yet reached the 1-year mark. The calculation of
EOA was restricted to 87 cases with adequate echographic
visibility to allow for secure measures of subaortic diameter
and flow calculations. Transesophageal echocardiography
was not performed. At each follow-up, M-mode, 2-dimen-
sional, and Doppler echocardiography was performed.
Standard apical, parasternal, and subcostal views were
obtained. The following parameters were measured: LV end-
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Table I. Patient characteristics
No. of patients 171/567 (30.1%)
Age (y)





Size of the aortic anulus
19 mm 47/171 (27.5%)
21 mm 124/171 (72.5%)
BSA (m2)
19-mm anulus 1.55 ± 0.2





Sinus rhythm 130 (76%)
Atrial fibrillation 29 (17%)
Complete heart block 12 (7%)
Coronary artery disease 39 (22.8%)
Mitral valve disease 21 (12.2%)
New York Heart Association
Class I-II 28 (16%)
Class III-IV 143 (84%)
Fig 1. The CryoLife-O’Brien porcine stentless aortic valve.
systolic and end-diastolic diameters, ejection fraction and
fractional shortening, interventricular septum and posterior
wall thickness, and maximum and mean flow velocity across
the stentless valve. The following parameters were then cal-
culated: LV mass was calculated from M-mode measure-
ments with the formula modified by Devereux and Reicher;
maximum and mean aortic valve gradients were calculated by
a modified Bernoulli equation; the EOA was calculated by
the continuity equation; the values of EOA and of LV mass
were indexed for BSA, the results of which were averaged.
Complication rates for primary and secondary events.
Operative and long-term mortality and morbidity information
was collected during the 6-year follow-up period with the
guidelines of Edmund and associates10 for reporting morbid-
ity and mortality information after cardiac valvular opera-
tions.
Statistical analysis. Discrete variables are presented as
counts and percentages. Continuous variables are presented
as means ± SD. For complication rates, both the simple per-
centage of patients with early events (<30 days) and lin-
earized rates for late events (>30 days) are reported.
Linearized rates (in percentage per patient-year) were calcu-
lated by dividing the number of events by patient-years of fol-
low-up and multiplying by 100%. Survival was determined
by the Kaplan-Meier product limit method. Comparison over
a time period of 2 continuous variables with normal distribu-
tion (gradients EOA and LV mass) were assessed by the
Student t test.
Results
The 30-day mortality rate was 3.5% (6 patients: 2,
emergency redo operations; 1, sepsis; 1, mitral annular
disruption; 1, bleeding; and 1, myocardial infarction).
During the early years of the study, all patients were
given oral anticoagulants over a 2- to 3-month period,
maintained only in the presence of atrial fibrillation.
Presently most patients receive only low-dose aspirin
after the operation. Echographic measurements of gra-
dients, EOA, and LV mass at discharge and after 1 year
are reported in Table II. Differences in all groups are
significant with P < .001. During the first year,
improved hemodynamics can be demonstrated in most
patients. Regurgitation is absent or a trace. None of the
patients underwent cardiac catheterization.
At the time of this report 92 patients have reached the
2-year follow-up interval; 61 patients have reached the
3-year mark; 42 patients, the 4-year mark; 25 patients,
the 5-year mark; and 14 patients, the 6-year limit,
which accounts for a cumulated follow-up of 401
patient-years. Complication rates for secondary events
are listed in Table III. Follow-up was 99% complete
with 2 patients lost for follow-up. Ninety-two percent
of the patients are in New York Heart Association class
I-II. The 6-year survival is 87% ± 5%. 
Discussion
The increasing number of elderly patients who
undergo operations for senescent calcification of the
aortic valve reflects the satisfactory outlook for opera-
tive survivors with symptomatic relief and regained
autonomy in most instances.11 Tissue valves are the
preferred prosthesis in this population because of the
shorter life expectancy and good durability of tissue
prostheses in patients over 70 years of age.
A small aortic root is not an uncommon finding in
elderly patients.12 In our present study group, we
encountered a small aortic anulus in 30% of the
patients. In patients over 80 years of age, the percent-
age reaches 40%. The prevalence of a 19-mm root was
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Table II. Hemodynamic data of CryoLife-O’Brien
stentless valves in patients with an aortic anulus of 19
and 21 mm
19 mm 21 mm
Mean gradients (mm Hg)
Before the operation 52.5 ± 30.4 57.5 ± 19.8
Discharge 12 ± 4.8 10.5 ± 2
1 Year 9 ± 2 6 ± 1.7
EOA (cm2)
Discharge 1.25 ± 0.1 1.58 ± 0.6
1 Year 1.45 ± 0.3 1.72 ± 0.4
Effective area index (cm2/m2)
Discharge 0.80 ± 0.1 0.88 ± 0.1
1 Year 0.93 ± 0.1 0.96 ± 0.1
LV mass (g)
Before the operation 296 ± 127 281 ± 75
1 Year 215 ± 102 236 ± 15
LV mass index (g/m2)
Before the operation 190 ± 48 157 ± 34
1 Year 138 ± 36 133 ± 8
Table III. Complication rate for secondary events
Linearized rate
Event No. (%/pt-y)
Structural valve deterioration 0 0
Nonstructural dysfunction 0 0
Valve thrombosis 0 0
Embolism 2 0.4
Anticoagulant-related bleeding 0 0
Operated valvular endocarditis 2 0.4
Reoperation 2 0.4
Nonfatal cardiac events 2 0.4
(myocardial infarction)
Valve-related death 1 0.2
Cardiac deaths 0 0
Total deaths 5 1.2
8% and that of a 21-mm root, 28%. Patients with a
small aortic root and a BSA of more than 1.70 m2 are
considered to be at risk of replacement device mis-
match that is responsible for suboptimal hemodynamic
performance and higher residual postoperative gradi-
ents. Stented valves constructed with bovine pericardi-
um show no significant improvement compared with
porcine valves in respect to transvalvular gradients and
EOA in the small sizes13-15 and therefore do not pre-
clude the necessity of enlarging the aortic anulus in
selected active elderly patients. The Manougian tech-
nique allows accommodating stented prostheses 1 or 2
sizes larger than what would have been possible with-
out enlargement. In this respect, the Manougian tech-
nique is efficient, but a certain reluctance always
remained in performing these more extensive opera-
tions in elderly patients who may also have fragile and
calcified ascending aortas.16,17
What are the advantages of obtaining optimal hemo-
dynamics after AVR? It is amply demonstrated that low
gradients correlate with a more complete regression of
LV hypertrophy and enhance recovery of LV systolic
and diastolic function. Del Rizzo and associates18 stud-
ied serial echocardiograms and showed a statistical
relationship between residual pressure gradients and
LV mass. Monrad and associates19 studied LV mass
index 5 to 10 years after the operation and found com-
pelling evidence that LV hypertrophy persists because
of the obstructive nature of the replacement device.
What are the long-term effects of persistent hypertro-
phy? Although we are lacking randomized controlled
studies, there are some indications toward a deleterious
effect of persistent hypertrophy that suggests that
patient-device mismatch has an influence on long-term
survival. He and associates20 reported on a 30-year fol-
low-up of 404 patients who had undergone AVR with
small aortic roots and showed that mismatch is a nega-
tive determinant of long-term survival. Lund and asso-
ciates21 brought indirect evidence about the influence
of residual gradients after AVR: among 176 late deaths,
23.9% were due to sudden cardiac deaths and 30%
were due to congestive heart failure. Residual hyper-
trophy affects the systolic and diastolic ventricular
function, so it appears that the size and type of the
valve has an important bearing on postoperative LV
performance.22-24 Walter and associates25 showed that,
although patients have a decrease in LV mass after
AVR, it was greater in those with stentless valves. The
nonrandomized study of David and associates26 case-
matched the patients who received the Toronto SPV
valve (St Jude Medical, Inc, St Paul, Minn) with those
patients who received the Hancock II valve (Medtronic,
Inc, Minneapolis, Minn). When the duration of follow-
up exceeds 5 years, the actuarial survival of patients
with a stentless valve is 93% versus 86%. There is a
strong suggestion that improved hemodynamics and
LV function translates directly into better event-free
survival. In contradiction, the study by Sawant and
associates27 claims that using a 19-mm St Jude Medical
valve for AVR in patients with a BSA of more than l.70
was not a determinant of long-term survival. Christakis
and Goldman,28 however, considered the study to be
underpowered in respect to the follow-up and number
of cases, forbidding firm conclusions.
All large studies agree that stentless valves demon-
strate excellent hemodynamics, superior to those
encountered with stented models. This feature seemed
attractive for patients with small aortic roots and was
expected to allow AVR without having to enlarge the
anulus.
The CryoLife-O’Brien stentless prosthesis has
proved to be easy to handle in the presence of a small
aortic root. The low transprosthetic gradients obtained
in the study group and the effective orifice index supe-
rior to 0.8 cm2/m2 met with our expectations and ruled
out the need to take into consideration the individual
patient’s BSA and the anticipated physical activity.
Comparable results have been reported with other types
of stentless valves; for instance, the 21-mm and the 23-
mm CryoLife-O’Brien stentless valve inserted in
patients with a 19-mm and 21-mm aortic anulus,
respectively, produces results that are very close to the
reported results of 21- and 23-mm Medtronic Freestyle
or Toronto SVP. Lower residual gradients and larger
EOAs correlate with a substantial regression of LV
hypertrophy, a major determinant of LV function and
possibly of long-term clinical status.
Finally, the gradients recorded with the unstented
valves selected for a 19- or 21-mm aortic anulus are
lower6,8,9 than those reported for 19- or 21-mm
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Table IV. Hemodynamic data of 4 valves used for a
19-mm or a 21-mm aortic anulus
Aortic anulus 19 mm 21 mm
CryoLife-O’Brien* 12 ± 4.2 9 ± 2
Carpentier-Edwards pericardial† 26.3 ± 9.4 22.6 ± 9.7
Medtronic Hall‡ 17 ± 5 8 ± 4
St Jude Medical§ 22 ± 7 12 ± 5
Mean gradients, mm Hg ± SD.
*Present study.
†MacDonald et al: Ann Thorac Surg 1997;63:362-6.14
‡Manufacturer’s data.
§Panidis et al. J Am Coll Cardiol 1986;8:317-26.30
mechanical valves30 (Table IV). Therefore mechanical
valves should not necessarily be considered as an alter-
native to annular enlargement in elderly patients with
small aortic roots, and surgeons should become famil-
iar with the unstented porcine valves.
Conclusion
The CryoLife-O’Brien stentless porcine prostheses
leaves only mild residual obstruction in the subgroup of
elderly patients with a small aortic root. There is
presently no indication to enlarge the aortic anulus,
regardless of the patient’s BSA and anticipated exercise
capacity. Residual gradients are consistently low, and
an EOA index above 0.9 cm2/m2 at 1 year makes it our
valve of choice for AVR in the elderly patient with a
small aortic root.
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Discussion
Dr Edward D. Verrier (Seattle, Wash). Thank you for the
opportunity to discuss this multicenter, multinational trial of
the CryoLife-O’Brien stentless bioprosthesis in small aortic
roots. 
Stentless aortic prostheses are receiving increasing atten-
tion as a viable and potentially preferred prosthesis in the aor-
tic position, as our understanding of the LV outflow tract, aor-
tic valve, and aortic root physiology and pathology evolve.
Insights into this pathophysiology have increased with the use
of echocardiography, particularly now 3-dimensional
echocardiography, computer modeling, such as finite element
analysis, and extensive surgical experience. 
The reported potential advantages of the stentless valve
technology include lower peak and mean gradients and there-
fore greater EOAs, particularly in the smaller sizes, acceler-
ated reduction of LV wall mass, and remodeling of the ven-
tricle, thereby enhancing recovery of both systolic and
diastolic function, no need of warfarin anticoagulation, and
even a hint of improved long-term survival. 
The reported potential disadvantages of the stentless tech-
nology include greater technical demands at the time of inser-
tion and lack of any long-term data concerning durability. 
I have a few concerns related to the study design and con-
clusions. The measurement of LV wall mass can be particu-
larly difficult, variable, and operator-dependent. How did you
assure consistency and quality of the echocardiographic mea-
surements with 4 centers in 4 countries? Was consideration
given to an independent observer reviewing the echocardio-
grams, blinded to either the size of the valve inserted or the
site of implantation? I believe this would have significantly
strengthened the conclusions of the trial. 
In almost all other studies of stentless valves, the relative
percentage of 19- and 21-mm valves is smaller than the 30%
reported incidence in this series. Now, this may reflect differ-
ent sizing techniques based on various valve manufacturing
specifications. One other thought is that to achieve the bene-
fits or the potential benefits of stentless technology, signifi-
cantly greater annular debridement is required to maximally
relieve any LV outflow tract obstruction. In addition, valve
relations then become more determined by the sinus or the
sinotubular junction. How much annular debridement was
required in this to achieve the remodeling that is associated
with this stentless-type valve? 
The measurement of EOA is a calculated number based on
cardiac index, even though it is widely used for valve com-
parisons. How was this done in your investigation? This is
important because the EOAs reported in this series are con-
siderably larger than any other series of stentless or stented
bioprostheses. How is that achieved when the effective anu-
lus is 19 or 21 mm if you do not do the debridement, partic-
ularly if you leave residual calcium in the anulus?
Overall, this is an excellent study for the early and late
results of the stentless prosthesis; it uses a multicentered
design, and it also gives significant insights into a number of
the problems that we have in measurement and in comparison
of these various prostheses. I believe that all of us are going
to have to make sure we know the standardization of these
measurements for these conclusions to extend from one
series to the next. 
Dr Hvass. I agree with you that the parameters that we are
using to evaluate these valves are very observer-dependent
and that there were differences between the 4 different teams,
especially in masses and even more in EOA. I know that we
have low gradients and small EOAs when compared with the
series of Mark O’Brien, who has slightly higher gradients and
even larger EOAs. So there is an individual variation and also
differences in the teams. But, once put together, it is interest-
ing to see that, generally speaking, we are all tending to the
same excellent results. 
Concerning LV masses, it is fairly obvious that we know
the calculations of LV mass. There is a great variation, and
there is a mean error that could go up to 30%, so it is not a
very precise parameter either. I think we are lacking precise
parameters to evaluate these valves, that seems pretty obvi-
ous, because the exact size and the exact dimension of the
subvalvular area will vary considerably with the observer. 
There was a question also about debridement. I think you
have to take out as much calcium as you can. You have to
have a flexible anulus and a flexible aortic root. At times we
have to take out layers of calcium that are in the sinuses or
near the commissures.
Measuring, it has been a straightforward type of measur-
ing. We have been using Hagar probes, which are much more
sensitive and much more reliable than any other types of
measurers.
Dr Stephen Westaby (Oxford, England). One thing puz-
zles me. In both the Freestyle and Toronto valves, the trans-
valvular gradients fall with time and the EOA increases.
These findings are not due to changes in the valve itself but
to rapidly improving LV function. Your parameters did not
change, according to your abstract. Could you speculate as to
the difference between the O’Brien valve and the Toronto and
the Freestyle valves?
Dr Hvass. I thought there was a change. There was a
change between measurements at discharge and at 1 year in
gradients and EOA.
Dr Tirone E. David (Toronto, Ontario, Canada). Were the
changes significant? 
Dr Hvass. Yes, the changes were significant. 
Dr David. So the valve did increase the orifice with time? 
Dr Hvass. There was an increased orifice. I do not know
where it comes from, if it comes from a better LV function or
not, but there was a difference there. I think all these stentless
valves behave in the same way. The techniques to insert them
are a little different and one gets used to one or the other, but
finally the immediate and long-term results, or at least up
until now, have been exactly the same.
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